adsilico Raises £10M for Virtual Patient Testing

Testing a medical device against a wider range of patient anatomies is difficult when physical prototypes and clinical studies are expensive. A Leeds spinout is trying to move more of that investigation into simulation.

What happened

University of Leeds spinout adsilico raised £10 million in Series A funding led by PXN Ventures, with Northern Gritstone and Parkwalk participating.

Its Virtual Chimera platform combines AI-generated representations of human anatomy with physics-based models to simulate how medical devices may perform. The initial applications include cardiovascular devices and implants, where anatomy and mechanical behaviour can vary considerably between patients.

The approach aims to help designers investigate performance across virtual populations before some of the more costly stages of development. These simulations generate additional evidence; they do not automatically replace human clinical studies or regulatory requirements.

Why it matters

Traditional medical-device development relies on bench testing, animal studies where applicable and human evidence. Each stage has limitations, and clinical trials cannot economically represent every possible anatomical variation.

Validated computational models could let manufacturers identify potential problems earlier and improve how they select device designs for further testing. That could reduce wasted development cycles and support better evidence packages, although acceptance depends on model credibility and the specific regulatory context.

The bigger picture

AI in healthcare is not limited to diagnosing patients or finding drug molecules. It is also becoming an engineering tool for the devices used in treatment. The interesting commercial opportunity is in making virtual testing reliable enough to become part of everyday product development, rather than a demonstration used alongside conventional processes.